N.K. Orazymbetova
Research Subjects
N.K. Orazymbetova has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
O.N. Serikbayov
ТОО Научно исследовательский институт проблем биологической безопасности, АО Национальный холдинг «QazBioPharm
2 shared publications- Zhumagali K. Koshemetov
Research Institute for Biological Safety Problems, National Holding “QazBioPharm”, Gvardeyskiy 080409, Kazakhstan
2 shared publications - Aigerim Zhakypbek
Research Institute for Biological Safety Problems, National Holding QazBioPharm, Gvardeiskiy 080409, Kazakhstan
1 shared publication B.K. Umuraliev
ТОО Научно исследовательский институт проблем биологической безопасности, Национальный холдинг «QazBioPharm
1 shared publicationNational Holding «QazBioPharm» "Research Institute of Biological Safety Problems
1 shared publicationNational Holding «QazBioPharm» ‘Research Institute of Biological Safety Problems
1 shared publication
Latest Publications
- Open Access
- 30 September 2025
- Published by West Kazakhstan Agrarian Technical University named after Zhangir Khan in Ġylym ža̋ne bìlìm
- Vol. 80 (3) , 386-396
PREPARATION OF A SPECIFIC ANTIGEN FOR DIAGNOSTICS OF THE ORTHOPOXVIRUS GENUS OF THE POXVIRIDAE FAMILY
The paper presents the process of obtaining a specific antigen from the smallpox vaccine virus, characterized by high specificity and biological activity, suitable for the detection of antibodies to members of the Orthopoxvirusgenus (family Poxviridae). The obtained antigen can be used in serological studies for the diagnosis of infections caused by Orthopoxvirusspecies, as well as for epidemiological monitoring and evaluation of the effectiveness of vaccine prophylaxis.For cultivation, a human cervical cancer cell line (HeLa) infected with the smallpox vaccine virus at a titer of at least 4.5 log TCID₅₀/cm³ was used. After concentration of the virus-containing suspension and triple thermolysis, purification was performed by centrifugation in a sucrose gradient. As a result of ultracentrifugation, the antigen fraction was concentrated mainly in the 40–60% sucrose zone. The resulting antigen was further analyzed for purity and identity using immunoblotting.Electrophoretic analysis (SDS-PAGE) confirmed the presence of protein fractions with molecular weights ranging from 14 to 80 kDa. The most intense bands corresponded to the main structural proteins of the virus: A56R (85–89 kDa), A10L (62 kDa), and A27L (14 kDa). The purification process significantly reduced the level of non-specific proteins, confirmingthe effectiveness of the method used. The results indicate a high degree of purity of the preparation and its suitability for further immunological and structural studies.The obtained antigen demonstrated high activity in serological assays: in the agar diffusion precipitation reaction -up to 1:64, and in the prolonged complement fixation test —up to 1:256, showing specific reactivity only with sera against viruses of the Poxviridaefamily. Thus, the specific antigen of the smallpox vaccine virus can beused for the development of immunological tests and in studies aimed at diagnosing orthopoxvirus infections.Additionally, the data confirm the potential of using this antigen as a marker in serological monitoring and rapid diagnostic systems, which couldsignificantly enhance the effectiveness of epidemiological surveillance and the timely detection of Orthopoxvirus-induced infections
- 30 September 2025
- Published by West Kazakhstan Agrarian Technical University named after Zhangir Khan in Ġylym ža̋ne bìlìm
- Vol. 80 (3) , 386-396
Open AccessPREPARATION OF A SPECIFIC ANTIGEN FOR DIAGNOSTICS OF THE ORTHOPOXVIRUS GENUS OF THE POXVIRIDAE FAMILY
The paper presents the process of obtaining a specific antigen from the smallpox vaccine virus, characterized by high specificity and biological activity, suitable for the detection of antibodies to members of the Orthopoxvirusgenus (family Poxviridae). The obtained antigen can be used in serological studies for the diagnosis of infections caused by Orthopoxvirusspecies, as well as for epidemiological monitoring and evaluation of the effectiveness of vaccine prophylaxis.For cultivation, a human cervical cancer cell line (HeLa) infected with the smallpox vaccine virus at a titer of at least 4.5 log TCID₅₀/cm³ was used. After concentration of the virus-containing suspension and triple thermolysis, purification was performed by centrifugation in a sucrose gradient. As a result of ultracentrifugation, the antigen fraction was concentrated mainly in the 40–60% sucrose zone. The resulting antigen was further analyzed for purity and identity using immunoblotting.Electrophoretic analysis (SDS-PAGE) confirmed the presence of protein fractions with molecular weights ranging from 14 to 80 kDa. The most intense bands corresponded to the main structural proteins of the virus: A56R (85–89 kDa), A10L (62 kDa), and A27L (14 kDa). The purification process significantly reduced the level of non-specific proteins, confirmingthe effectiveness of the method used. The results indicate a high degree of purity of the preparation and its suitability for further immunological and structural studies.The obtained antigen demonstrated high activity in serological assays: in the agar diffusion precipitation reaction -up to 1:64, and in the prolonged complement fixation test —up to 1:256, showing specific reactivity only with sera against viruses of the Poxviridaefamily. Thus, the specific antigen of the smallpox vaccine virus can beused for the development of immunological tests and in studies aimed at diagnosing orthopoxvirus infections.Additionally, the data confirm the potential of using this antigen as a marker in serological monitoring and rapid diagnostic systems, which couldsignificantly enhance the effectiveness of epidemiological surveillance and the timely detection of Orthopoxvirus-induced infections
- Open Access
- 30 September 2025
- Published by West Kazakhstan Agrarian Technical University named after Zhangir Khan in Ġylym ža̋ne bìlìm
- Vol. 80 (3) , 397-408
PRODUCTION OF HUMAN ANTI-SPECIES SERUM FOR SEROLOGICAL DIAGNOSIS OF POST-VACCINATION IMMUNITY AGAINST MONKEYPOX
Despite the global eradication of smallpox in 1977, the virus continues to pose a significant biosafety threat due to its potential use as a biological weapon. The smallpox virus is relatively easy to culture, can be preserved through lyophilization (freeze-drying), and remains stable when protected from high temperatures and ultraviolet radiation. These characteristics underscore the ongoing need for vigilant epidemiological surveillance, as well as the continued development of modern vaccines and reliable diagnostic tools.In this study, an attempt was made to obtain a human-specific antiserum suitable for the development of an enzyme-linked immunosorbent assay (ELISA) intended to evaluate the effectiveness of smallpox vaccines. Human γ-globulin, isolated by the Kohn alcohol fractionation method at a final concentration of 12.54 mg/mL, was used as the antigen. Laboratory animals—goats of local breeds and rabbits weighing 2–2.5 kg—were used to produce the antispecific serum. The immunization regimens varied in terms of the antigen doses administered, the intervals between injections, and the sites of administration.As a result of the experimental work, it was found that serum obtained from rabbits following immunization scheme No. 1 demonstrated the highest specific activity, with a titer of 1:64 in the diffusion precipitation reaction. This rabbit-derived antiserum will be used as the primary diagnostic reagent for optimizing ELISA conditions aimed at detecting antibodies to the Monkeypox virus.The development of highly specific and sensitive diagnostic methods, such as ELISA based on well-characterized antispecific sera, is critical for effective epidemiological monitoring. This is especially relevant in light of the re-emergence of orthopoxviruses like Monkeypox and the persistent threat of deliberate virus release. Continued advancements in diagnostic reagents will enhance public health preparedness and response strategies for orthopoxvirus-related diseases
- 30 September 2025
- Published by West Kazakhstan Agrarian Technical University named after Zhangir Khan in Ġylym ža̋ne bìlìm
- Vol. 80 (3) , 397-408
Open AccessPRODUCTION OF HUMAN ANTI-SPECIES SERUM FOR SEROLOGICAL DIAGNOSIS OF POST-VACCINATION IMMUNITY AGAINST MONKEYPOX
Despite the global eradication of smallpox in 1977, the virus continues to pose a significant biosafety threat due to its potential use as a biological weapon. The smallpox virus is relatively easy to culture, can be preserved through lyophilization (freeze-drying), and remains stable when protected from high temperatures and ultraviolet radiation. These characteristics underscore the ongoing need for vigilant epidemiological surveillance, as well as the continued development of modern vaccines and reliable diagnostic tools.In this study, an attempt was made to obtain a human-specific antiserum suitable for the development of an enzyme-linked immunosorbent assay (ELISA) intended to evaluate the effectiveness of smallpox vaccines. Human γ-globulin, isolated by the Kohn alcohol fractionation method at a final concentration of 12.54 mg/mL, was used as the antigen. Laboratory animals—goats of local breeds and rabbits weighing 2–2.5 kg—were used to produce the antispecific serum. The immunization regimens varied in terms of the antigen doses administered, the intervals between injections, and the sites of administration.As a result of the experimental work, it was found that serum obtained from rabbits following immunization scheme No. 1 demonstrated the highest specific activity, with a titer of 1:64 in the diffusion precipitation reaction. This rabbit-derived antiserum will be used as the primary diagnostic reagent for optimizing ELISA conditions aimed at detecting antibodies to the Monkeypox virus.The development of highly specific and sensitive diagnostic methods, such as ELISA based on well-characterized antispecific sera, is critical for effective epidemiological monitoring. This is especially relevant in light of the re-emergence of orthopoxviruses like Monkeypox and the persistent threat of deliberate virus release. Continued advancements in diagnostic reagents will enhance public health preparedness and response strategies for orthopoxvirus-related diseases